{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T01:00:47Z","timestamp":1705539647739},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.beha.2005.11.005","type":"journal-article","created":{"date-parts":[[2006,3,3]],"date-time":"2006-03-03T12:34:11Z","timestamp":1141389251000},"page":"293-300","source":"Crossref","is-referenced-by-count":8,"title":["Myelodysplasia: When to treat and how"],"prefix":"10.1016","volume":"19","author":[{"given":"Richard A.","family":"Larson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2005.11.005_bib1","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2002-11-3325","article-title":"A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.11.005_bib2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/BF03324506","article-title":"Effects of influenza vaccination on mortality among frail, community-living elderly patients: an observational study","volume":"15","author":"Landi","year":"2003","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.beha.2005.11.005_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-1-4615-1463-3_13","article-title":"Special clinical concerns\/problems in the management of MDS and secondary acute myeloid leukemias","volume":"108","author":"Venugopal","year":"2001","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.beha.2005.11.005_bib4","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"supplement 1","key":"10.1016\/j.beha.2005.11.005_bib5","first-page":"21","article-title":"Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes","volume":"7","author":"Silverman","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2005.11.005_bib6","first-page":"A12","article-title":"Azacytidine in myelodysplastic syndromes: CALGB studies 8421 and 8921","volume":"68","author":"Silverman","year":"1994","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2005.11.005_bib7","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2005.11.005_bib8","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","article-title":"Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study","volume":"20","author":"Kornblith","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2005.11.005_bib9","doi-asserted-by":"crossref","first-page":"23a","DOI":"10.1182\/blood.V104.11.67.67","article-title":"First report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS)","volume":"104","author":"Saba","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.11.005_bib10","doi-asserted-by":"crossref","first-page":"402a","DOI":"10.1182\/blood.V104.11.1437.1437","article-title":"Decitabine low-dose schedule (100mg\/m2\/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules","volume":"104","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.11.005_bib11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2005.11.005_bib12","doi-asserted-by":"crossref","first-page":"2s","DOI":"10.1200\/jco.2005.23.16_suppl.5","article-title":"Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study","volume":"23","author":"List","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2005.11.005_bib13","unstructured":"Hugin RJ, Gill BP of Celgene Corporation. Preliminary Clinical Data presented on Revlimid (TM) in Malignant Blood Disorders, December 5, 2004, http:\/\/ir.celgene.com\/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=650409&highlight=., http:\/\/ir.celgene.com\/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=650409&highlight=."},{"key":"10.1016\/j.beha.2005.11.005_bib14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1182\/blood.V95.4.1188.004k38_1188_1194","article-title":"Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55\u201366 years of age","volume":"95","author":"Deeg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.11.005_bib15","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1182\/blood.V99.6.1943","article-title":"Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program","volume":"99","author":"Castro-Malaspina","year":"2002","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692605001076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692605001076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T01:02:28Z","timestamp":1586739748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692605001076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S1521692605001076"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2005.11.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}